Sutro Biopharma Förvaltning
Förvaltning kriterier kontrolleras 2/4
Sutro Biopharma VD är Jane Chung, utsedd i Mar 2025, har en mandatperiod på 1.08 år. totala årliga ersättningen är $ 1.58M, bestående av 41.4% lön 58.6% bonusar, inklusive företagsaktier och optioner. äger direkt 0.13% av företagets aktier, värda $ 753.27K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 1 år respektive 5.9 år.
Viktig information
Jane Chung
Verkställande direktör
US$1.6m
Total ersättning
| VD-lön i procent | 41.37% |
| Anställning som VD | 1.1yrs |
| Ägande av VD | 0.1% |
| Ledningens genomsnittliga anställningstid | less than a year |
| Styrelsens genomsnittliga mandatperiod | 5.9yrs |
Senaste uppdateringar av ledningen
Recent updates
Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell
May 01
STRO: ADC Progress And Equity Offering Will Shape Balanced Future Outlook
Analysts have raised their price target for Sutro Biopharma by about $2, reflecting updated fair value estimates along with revised assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Sutro reported promising preclinical data for multiple next generation antibody drug conjugates (ADCs), including STRO-004, STRO-006 and STRO-227, at the American Association for Cancer Research Annual Meeting 2026.STRO: Equity Offering And Lockup Structure Will Support Future Upside
Analysts now place Sutro Biopharma's price target at about $30.11, up from roughly $27.88. This reflects updated assumptions around fair value, discount rate, future revenue trends, profit margin, and a higher future P/E of about 199x.STRO: Recent Equity Raises And Lockup Structure Will Support Future Upside
Analysts have revised their price target for Sutro Biopharma from $21.25 to $27.88, reflecting updated assumptions around discount rate, revenue growth, profit margin, and a higher future P/E in their models. What's in the News Sutro Biopharma filed a follow-on equity offering of up to US$100 million in common stock as an at-the-market program, providing flexibility to issue shares over time.
STRO: Equity Raise And Index Removal Will Set Up Future Upside Potential
Analysts have kept their $51.00 price target on Sutro Biopharma unchanged, as a slightly lower discount rate and a higher assumed future P/E multiple are seen as offsetting a softer revenue outlook and reduced profit margin expectations. What's in the News Sutro Biopharma completed a follow on equity offering of approximately US$110.0 million, issuing 7,868,383 common shares at US$13.98 per share with a US$0.8388 discount per share (Key Developments).STRO: Reverse Split And Equity Raise Will Support Future Upside
Analysts have inched up their price target on Sutro Biopharma to $21.25 from $21, citing updated assumptions that include a slightly lower discount rate, modest changes to long term profit margin expectations, and a higher future P/E multiple. What's in the News Sutro Biopharma completed a follow on equity offering of common stock, raising about US$110.0m through the sale of 7,868,383 shares at US$13.98 per share, reflecting a US$0.8388 per share discount (Key Developments).STRO: Reverse Split And ADC Pipeline Progress Will Support Future Upside Potential
Analysts have maintained their price target on Sutro Biopharma at US$51.00, making only minor adjustments to their models. Slightly softer assumptions for long-term revenue growth and profit margins are largely offset by a higher future P/E multiple.Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation
Feb 04
STRO: Reverse Split And ADC Pipeline Progress Will Drive Future Upside
Analysts lifted their price target on Sutro Biopharma to US$51.00 per share, highlighting updated assumptions around fair value, discount rate, revenue growth expectations, profit margins, and a slightly lower future P/E as the key drivers of the change. What's in the News Sutro Biopharma regained compliance with Nasdaq’s continued listing standard for minimum share price under Rule 5450(a)(1) after its common stock maintained an average closing price of at least US$1.00 following a 1:10 reverse stock split effective December 3, 2025 (company announcement).STRO: Reverse Split And ADC Pipeline Progress Will Support Future Upside
Analysts have trimmed their price target on Sutro Biopharma from US$22.29 to US$21.00, citing updated assumptions that include a slightly lower discount rate, a wider expected revenue decline of about 6.3 percentage points, a modestly higher profit margin, and a higher future P/E multiple. What's in the News Sutro Biopharma was removed from the Nasdaq Biotechnology Index, which can affect index fund ownership that tracks this benchmark (Index Constituent Drops).Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 46%
Dec 31STRO: Reverse Split And ADC Pipeline Focus Will Drive Future Upside
Narrative Update on Sutro Biopharma Analysts have reduced their price target on Sutro Biopharma from approximately $28.00 to about $22.30 per share. This reflects a lower assumed future price to earnings multiple, while expectations for revenue growth and profit margins remain largely unchanged.STRO: Reverse Split And ADC Focus Will Drive Long-Term Upside
Analysts have raised their price target on Sutro Biopharma from 2.69 dollars to 28.00 dollars, citing expectations for improved long term profit margins despite softer revenue growth assumptions and a modestly higher discount rate. What's in the News Sutro Biopharma approved a 1 for 10 reverse stock split or significant stock dividend effective December 3, 2025, aimed at improving its share price profile for investors (company announcement).ADC Pipeline Focus Will Advance Preclinical Drug Development
The downward revision in Sutro Biopharma’s price target reflects worsening net profit margin and deeper negative revenue growth forecasts, with fair value decreasing from $3.11 to $2.69. What's in the News Sutro Biopharma entered a collaboration with the FDA to co-develop reference materials and improve regulatory standards for ADC drug development, leveraging Sutro's XpressCF technology and FDA's analytical capabilities.Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation
Jul 01Benign Growth For Sutro Biopharma, Inc. (NASDAQ:STRO) Underpins Stock's 36% Plummet
Apr 18
ADC Pipeline Focus Will Advance Preclinical Drug Development
Strategic focus on preclinical programs and restructuring is set to drive future growth by enhancing drug development and revenue potential.Sutro Biopharma, Inc. (NASDAQ:STRO) Not Doing Enough For Some Investors As Its Shares Slump 25%
Mar 04Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless
Jan 02Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge
Nov 30Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive
Oct 11Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology
Sep 23There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise
Aug 24Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts
Aug 22Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results
Aug 16The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%
Jun 26We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right
May 31Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates
Apr 02The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet
Mar 28Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Dec 19Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?
Aug 24Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?
Feb 10An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued
Jan 12Sutro Biopharma: Partnership Progress Warrants Exposure
Aug 16Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Dec 31 2025 | US$2m | US$652k | -US$191m |
| Sep 30 2025 | n/a | n/a | -US$217m |
| Jun 30 2025 | n/a | n/a | -US$209m |
| Mar 31 2025 | n/a | n/a | -US$245m |
| Dec 31 2024 | US$1m | US$560k | -US$227m |
| Sep 30 2024 | n/a | n/a | -US$124m |
| Jun 30 2024 | n/a | n/a | -US$124m |
| Mar 31 2024 | n/a | n/a | -US$115m |
| Dec 31 2023 | US$1m | US$506k | -US$107m |
| Sep 30 2023 | n/a | n/a | -US$172m |
| Jun 30 2023 | n/a | n/a | -US$143m |
| Mar 31 2023 | n/a | n/a | -US$130m |
| Dec 31 2022 | US$1m | US$487k | -US$119m |
| Sep 30 2022 | n/a | n/a | -US$123m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | -US$114m |
| Dec 31 2021 | US$4m | US$188k | -US$106m |
Ersättning vs marknad: Jane s total kompensation ($USD 1.58M ) är under genomsnittet för företag av liknande storlek på US marknaden ($USD 2.57M ).
Ersättning vs inkomst: Ersättningen för Jane har ökat samtidigt som företaget är olönsamt.
VD OCH KONCERNCHEF
Jane Chung (54 yo)
1.1yrs
Anställning
US$1,575,930
Kompensation
Ms. Jane Chung, R.Ph., is Chief Executive Officer of Sutro Biopharma, Inc. from March 13, 2025 and served as its Chief Commercial Officer since August 09, 2021 until November 2023 and served as its Chief O...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | US$1.58m | 0.13% $ 753.3k | |
| Chief Financial Officer | less than a year | US$854.52k | 0.012% $ 69.9k | |
| Chief Scientific Officer | 2.6yrs | US$942.90k | 0.057% $ 336.9k | |
| Founder | no data | inga uppgifter | inga uppgifter | |
| Senior Vice President of Technical Operations | less than a year | inga uppgifter | inga uppgifter | |
| Chief Administrative Officer & General Counsel | 5.1yrs | inga uppgifter | 0.059% $ 345.0k | |
| Senior VP and Head of People & Culture | less than a year | inga uppgifter | inga uppgifter | |
| Vice President & Controller | no data | inga uppgifter | inga uppgifter | |
| Vice President of Clinical Development | no data | inga uppgifter | inga uppgifter |
1.0yrs
Genomsnittlig anställningstid
53yo
Genomsnittlig ålder
Erfaren ledning: STRO s ledningsgrupp anses inte vara erfaren ( 1 års genomsnittlig anställningstid), vilket föreslår ett nytt team.
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | US$1.58m | 0.13% $ 753.3k | |
| Independent Chair of the Board | 6.8yrs | US$121.80k | 0.030% $ 177.0k | |
| Independent Director | 6.3yrs | US$96.80k | 0% $ 0 | |
| Independent Director | 16.7yrs | US$95.30k | 0.014% $ 79.5k | |
| Chair of the Scientific Advisory Board | 5.9yrs | inga uppgifter | inga uppgifter | |
| Independent Director | 7.8yrs | US$86.80k | 0% $ 0 | |
| Independent Director | 9.2yrs | US$108.80k | 0% $ 0 | |
| Independent Director | 1.7yrs | US$99.30k | 0% $ 0 | |
| Independent Director | 5.4yrs | US$100.30k | 0% $ 0 | |
| Co-Chair of Clinical Advisory Board & Member of Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Director | 4.4yrs | US$99.30k | 0% $ 0 | |
| Member of the Clinical Advisory Board | 5.1yrs | inga uppgifter | inga uppgifter |
5.9yrs
Genomsnittlig anställningstid
66.5yo
Genomsnittlig ålder
Erfaren styrelse: STRO s styrelse anses vara erfaren ( 5.9 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/04/30 12:17 |
| Aktiekurs vid dagens slut | 2026/04/30 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Sutro Biopharma, Inc. bevakas av 17 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Tazeen Ahmad | BofA Global Research |
| Thomas Shrader | BTIG |